Paeds Cases · fetal-neonatal-and-perinatal
The preterm infant who stops weaning — a haemodynamically significant PDA
OSCE on a ventilated preterm infant with a haemodynamically significant patent ductus arteriosus, testing the assessment of significance, the expectant-first management ladder, the drug doses, the trial evidence, and the exclusion of a duct-dependent circulation.
On this page & tools
Target exams
Clinical information for the examiner
Setting: Tertiary NICU, day 5 of life. The infant is ventilated on volume-targeted ventilation (PIP 16, PEEP 5, rate 30, FiO₂ 0.42) for respiratory distress syndrome; antenatal steroids were given and one dose of surfactant administered at birth. The creatinine has risen from 78 to 102 µmol/L. [13]
On your arrival:
- Heart rate 158, SpO₂ 92%, blood pressure 52/24 (mean 34), widened pulse pressure 28. [13]
- Pulses bounding at the brachial and femoral arteries; precordium hyperdynamic. [13]
- Soft systolic murmur at the upper left sternal border. [13]
- Urine output 0.8 mL/kg/h (was 2.5). [13]
Functional echocardiogram (provided): structurally normal heart; duct diameter 2.1 mm with left-to-right flow; left atrial-to-aortic root ratio 1.7; diastolic flow reversal in the descending aorta; increased left ventricular output. [13]
Task 1 — Assess haemodynamic significance (3 marks)
The candidate should integrate the bedside and echocardiographic findings. [13]
- Bedside shunt signature: bounding pulses, hyperdynamic precordium, widened pulse pressure with a low diastolic (52/24). [13]
- End-organ compromise: oliguria and rising creatinine (systemic steal), escalating oxygen need (pulmonary over-circulation). [13]
- Echo constellation: duct 2.1 mm, LA:Ao 1.7, diastolic flow reversal in the descending aorta. [13]
Pass criterion: candidate states that significance is a constellation integrating the clinical end-organ signs with the echo, not a single threshold, and names the key markers. [13]
Task 2 — Expectant management first (3 marks)
The candidate must lead with expectant, supportive care, not the drug cupboard. [13]
- Correct hypoxia and acidosis (both relax the ductal smooth muscle); treat anaemia to preserve oxygen delivery. [13]
- Lung-protective ventilation with permissive hypercapnia; avoid fluid overload and modestly restrict intake. [13]
- Support the circulation with a vasoconstrictor if hypotension persists (volume boluses rarely help the steal); reduce or pause feeds to protect the gut. [13]
- Trend the urine output, creatinine, blood pressure and ventilator needs serially. [13]
Pass criterion: candidate frames expectant management as an evidence-based strategy, not inaction, and cites that most ducts close spontaneously. [13]
Task 3 — Pharmacological closure and doses (3 marks)
If the end-organ compromise progresses despite supportive care, pharmacological closure is indicated. [2]
- Ibuprofen: 10 mg/kg then 5 mg/kg at 24 and 48 hours (first-line). [2]
- Paracetamol: 15 mg/kg every six hours — preferred here given the rising creatinine, avoiding the renal vasoconstriction of the cyclo-oxygenase inhibitors. [4]
- Indomethacin: 0.2 mg/kg every 12 to 24 hours for three doses. [2]
Pass criterion: candidate gives correct doses and chooses paracetamol with a renal-sparing rationale, citing the Mitra network meta-analysis that all three beat placebo with ibuprofen and paracetamol favoured over indomethacin for safety. [2]
Task 4 — Evidence, safety and the ligation debate (2 marks)
Safety check: before any closure, confirm a structurally normal heart and exclude a duct-dependent circulation — closing a duct-dependent lesion is catastrophic. [13]
Evidence: the BeNeDuct trial (NEJM 2023) showed early ibuprofen was no better than expectant care, and PDA-TOLERATE showed treating at one week did not reduce death or bronchopulmonary dysplasia — anchoring the treat-the-infant approach. [1] [6]
Ligation: reserved for failure or contraindication; the association with adverse outcomes is confounded by indication (causality or bias). [10]
References
- [1]Hundscheid T, Onland W, Kooi EMW, et al Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. N Engl J Med, 2023.PMID 36477458
- [2]Mitra S, Florez ID, Tamayo ME, et al Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA, 2018.PMID 29584842
- [4]Jasani B, Mitra S, Shah PS Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev, 2022.PMID 36519620
- [6]Clyman RI, Liebowitz M, Kaempf J, et al PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr, 2019.PMID 30340932
- [10]Weisz DE, McNamara PJ Patent ductus arteriosus ligation and adverse outcomes: causality or bias? J Clin Neonatol, 2014.PMID 25024972
- [13]Mitra S, Weisz D, Jain A, et al Management of the patent ductus arteriosus in preterm infants. Paediatr Child Health, 2022.PMID 35273674